BeiGene
BGNE
#963
Rank
โ‚ฌ19.32 B
Marketcap
170,29ย โ‚ฌ
Share price
1.02%
Change (1 day)
5.83%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -15,87ย โ‚ฌ

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -16,05ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of -18,69ย โ‚ฌ a decrease over its 2021 EPS that were of -14,67ย โ‚ฌ.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-15,87ย โ‚ฌ-15.08%
2022-18,69ย โ‚ฌ27.35%
2021-14,67ย โ‚ฌ-19.96%
2020-18,33ย โ‚ฌ20.81%
2019-15,18ย โ‚ฌ31.52%
2018-11,54ย โ‚ฌ417.57%
2017-2,23ย โ‚ฌ-37.16%
2016-3,55ย โ‚ฌ158.95%
2015-1,37ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-0,96ย โ‚ฌ-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,26ย โ‚ฌ-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA